In this episode of Diagnosing Dx, I’m joined by Jake Lesinski, Co-founder and CEO of Checktor Biosciences, an ETH Zurich spin-out building a CRISPR-based chemistry platform designed to upgrade existing diagnostic systems rather than replace them.
We explore why speed, decentralisation, and practical integration, not hype, will define the next wave of molecular diagnostics. Jake shares how Checktor is approaching CRISPR from a clinical and commercial perspective, why matching PCR-level performance matters, and how distribution strategy can make or break even the strongest science.
This conversation is a grounded look at how diagnostics companies can scale responsibly, partner intelligently, and deliver real value to patients and healthcare systems.
Key takeaways:
🔹 Why rapid, accurate diagnostics remain one of healthcare’s biggest unmet needs
🔹 How CRISPR is finally finding its footing in real clinical workflows
🔹 Why upgrading existing diagnostic infrastructure beats starting from scratch
🔹 What founders need to understand about partnerships, validation, and scale
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics.